Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05557214
Other study ID # REB-22-38
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date May 2023
Est. completion date May 2024

Study information

Verified date April 2023
Source Saskatchewan Health Authority - Regina Area
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Approximately 90% of antibiotics are prescribed in primary healthcare (PHC) in Canada (Public Health Agency of Canada, 2020), making this an important sector for antimicrobial stewardship. Upper respiratory tract infections (URTIs) represent a common indication in PHC for which antibiotics are often prescribed unnecessarily (Leis et al, 2020; Schwartz et al., 2020). Reducing unnecessary antibiotic treatment in this sector is a vital part of contributing to minimizing the global burden of antibiotic resistance. The goal of this research project is to reduce the number of antibiotic prescriptions among family physicians identified as high prescribers in Saskatchewan. To achieve this, the investigators will send letters to the top 25th percentile of high prescribers in PHC. The letters will contain data indicating the prescribers high antimicrobial usage as well as guidance for reducing unnecessary prescriptions and promoting appropriate lengths of prescriptions for upper respiratory tract infections.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 2024
Est. primary completion date May 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - must be a practicing family physician in Saskatchewan - top 25th percentile of antimicrobial prescribers Exclusion Criteria: - fewer than 12 months of historical prescribing data available

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Audit and Feedback Letter
Physicians in the Audit and Feedback Letter Arm will receive an initial letter indicating their high prescriber status with guidance on reducing unnecessary antimicrobial use. They will also receive a follow-up letter at the 6 month mark indicating any change in prescribing habits. There will be a study closure letter mailed at the 12 month mark.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Saskatchewan Health Authority - Regina Area

References & Publications (2)

Leis JA, Born KB, Ostrow O, Moser A, Grill A. Prescriber-led practice changes that can bolster antimicrobial stewardship in community health care settings. Can Commun Dis Rep. 2020 Jan 2;46(1):1-5. doi: 10.14745/ccdr.v46i01a01. eCollection 2020 Jan 2. — View Citation

Schwartz KL, Langford BJ, Daneman N, Chen B, Brown KA, McIsaac W, Tu K, Candido E, Johnstone J, Leung V, Hwee J, Silverman M, Wu JHC, Garber G. Unnecessary antibiotic prescribing in a Canadian primary care setting: a descriptive analysis using routinely collected electronic medical record data. CMAJ Open. 2020 May 7;8(2):E360-E369. doi: 10.9778/cmajo.20190175. Print 2020 Apr-Jun. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Total Antibiotic Prescriptions Total number of antibiotic prescriptions compared to covariate-adjusted baseline number of prescriptions prior to the intervention. 12 months
Secondary Total Prolonged-Duration Prescription Number of prescriptions longer than 7 days. 12 months
Secondary Total Days of Therapy Number of days of therapy of antimicrobials for each provider. 12 months
Secondary Antibiotic Cost Total cost of prescribed antibiotics. 12 months
Secondary Total Specific Antibiotic Prescriptions Number of prescriptions for specific antibiotics. 12 months
See also
  Status Clinical Trial Phase
Completed NCT01158560 - A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections Phase 3
Completed NCT00965822 - A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population Phase 2
Completed NCT01019889 - Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection Phase 3
Not yet recruiting NCT05484102 - Preventive Effect of Cow's Milk Fermented With Lactobacillus Paracasei CBA L74 on Common Infectious Diseases in Children N/A
Recruiting NCT05804123 - LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media N/A
Terminated NCT01964885 - Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections Phase 3
Completed NCT01773824 - Routine Prescription Feedback and Peer Comparison to Lower Antibiotic Prescriptions in Primary Care N/A
Completed NCT01883427 - Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children Phase 2
Completed NCT01215682 - Vitamin D Supplementation and Upper Respiratory Tract Infections in Adolescent Swimmers N/A
Completed NCT04019730 - The Effect of a Ketogenic Diet on the Exercise Induced Immune Response N/A
Completed NCT01604096 - Controlled Trial to Evaluate a Local Information Campaign on Antibiotic Prescribing in Italy Phase 2
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Recruiting NCT03463694 - Edinburgh and Lothian Virus Intervention Study in Kids N/A
Completed NCT06127186 - Phenotype of Headache and Facial Pain in Upper Respiratory Tract Infections
Completed NCT03198676 - A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production Phase 1
Completed NCT01893762 - Innate Immune Response to (An)Aerobic Exercise in Rowing Athletes N/A
Completed NCT01129128 - Three Arm Trial of Immune Effects of Echinacea N/A
Completed NCT01396889 - Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years N/A
Completed NCT05252468 - COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19). N/A
Terminated NCT05279534 - Efficacy and Safety of L. Plantarum and P. Acidilactici in Children With Upper Respiratory Tract Infections N/A